Zobrazeno 1 - 4
of 4
pro vyhledávání: '"Benedetta Del Rio"'
Publikováno v:
Cancers, Vol 16, Iss 11, p 2018 (2024)
For patients diagnosed with advanced HER2-altered non-small cell lung cancer (NSCLC), the current standard of care is represented by a platinum-pemetrexed-based chemotherapy, eventually in combination with immunotherapy. Different pan-HER tyrosine ki
Externí odkaz:
https://doaj.org/article/77bae110b6284a29bc57ca18971dc896
Autor:
Edoardo Garbo, Benedetta Del Rio, Giorgia Ferrari, Massimiliano Cani, Valerio Maria Napoli, Valentina Bertaglia, Enrica Capelletto, Christian Rolfo, Silvia Novello, Francesco Passiglia
Publikováno v:
Cancers, Vol 15, Iss 19, p 4774 (2023)
Lung cancer represent the leading cause of cancer mortality, so several efforts have been focused on the development of a screening program. To address the issue of high overdiagnosis and false positive rates associated to LDCT-based screening, there
Externí odkaz:
https://doaj.org/article/71b118e0b988429fb66e15924b8a8622
Autor:
Massimiliano Cani, Valerio Maria Napoli, Edoardo Garbo, Giorgia Ferrari, Benedetta Del Rio, Silvia Novello, Francesco Passiglia
Publikováno v:
International Journal of Molecular Sciences, Vol 24, Iss 10, p 8883 (2023)
The clinical management of small cell lung cancer (SCLC) treatment remains a major challenge for thoracic oncologists, with very few therapeutic advances significantly impacting patients’ survival. The recent introduction of immunotherapy in the cl
Externí odkaz:
https://doaj.org/article/338e2d34e47c402c9a8108605d164219
Autor:
Irene Persano, Massimiliano Cani, Benedetta Del Rio, Giorgia Ferrari, Edoardo Garbo, Elena Parlagreco, Chiara Pisano, Valeria Cetoretta, Marco Donatello Delcuratolo, Fabio Turco, Alessandro Audisio, Cristina Cecchi, Gianmarco Leone, Valerio Maria Napoli, Valentina Bertaglia, Valentina Bianco, Enrica Capelletto, Carmen D’Amiano, Massimo Di Maio, Martina Gianetta, Silvia Novello, Francesco Passiglia, Giorgio Vittorio Scagliotti, Paolo Bironzo
Publikováno v:
Biomedicines, Vol 11, Iss 1, p 165 (2023)
Safety data regarding BNT162b2 in cancer patients (CPs) are scarce. Herein we report the side effects (SEs), the adverse events (AEs), and the patient-reported outcomes (PROs) following BNT162b2 administration in CPs treated at the San Luigi Gonzaga
Externí odkaz:
https://doaj.org/article/2e63b9cd60f041349dda710a43ca1131